Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $20,993.40 in Stock

Posted by Brenda Bartman on Oct 23rd, 2026

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) insider Scott Bizily sold 1,635 shares of the company’s stock in a transaction on Friday, October 16th. The shares were sold at an average price of $12.84, for a total value of $20,993.40. Following the completion of the sale, the insider directly owned 8,617 shares in the company, valued at $110,642.28. This trade represents a 15.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Scott Bizily also recently made the following trade(s):

On Wednesday, September 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $13.65, for a total value of $22,317.75.
On Tuesday, September 1st, Scott Bizily sold 584 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $14.00, for a total value of $8,176.00.
On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total transaction of $19,620.00.
On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.20, for a total transaction of $19,947.00.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT opened at $11.85 on Friday. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. The company’s 50-day moving average price is $14.07 and its 200 day moving average price is $11.61. 4D Molecular Therapeutics, Inc. has a 52 week low of $6.96 and a 52 week high of $16.93. The stock has a market cap of $654.59 million, a price-to-earnings ratio of -4.51 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. The business had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. As a group, research analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on FDMT shares. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Monday, August 17th. Citigroup reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Thursday. Bank of America increased their target price on 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday, September 29th. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Thursday, October 15th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $28.90.

Get Our Latest Report on 4D Molecular Therapeutics

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FDMT. Toth Financial Advisory Corp acquired a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth about $29,000. Legal & General Group Plc purchased a new stake in shares of 4D Molecular Therapeutics during the second quarter worth about $59,000. Sei Investments Co. raised its position in shares of 4D Molecular Therapeutics by 8.9% in the first quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock valued at $120,000 after buying an additional 1,050 shares during the last quarter. Rockefeller Capital Management L.P. raised its position in shares of 4D Molecular Therapeutics by 14,343.2% in the fourth quarter. Rockefeller Capital Management L.P. now owns 18,054 shares of the company’s stock valued at $135,000 after buying an additional 17,929 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of 4D Molecular Therapeutics in the second quarter valued at approximately $148,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

(Get Free Report)

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to design adeno-associated virus (AAV) vectors intended to deliver genetic medicines to specific tissues and organs.

Its pipeline has focused primarily on ophthalmology and pulmonology. Key investigational programs have included 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema, and 4D-710, an inhaled gene therapy designed to address the underlying cause of cystic fibrosis in patients who cannot benefit from existing CFTR modulator treatments.